Global Non Alcoholic Steatohepatitis Treatment Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Non Alcoholic Steatohepatitis Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Non Alcoholic Steatohepatitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Non Alcoholic Steatohepatitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Non Alcoholic Steatohepatitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Non Alcoholic Steatohepatitis Treatment players cover AstraZeneca Plc., Tobira Therapeutics Inc., Galmed Pharmaceuticals, Genfit SA, Zydus Cadila, Bristol Myers Squibb, Gilead Science, Conatus Pharmaceuticals Inc. and Novo Nordisk A/S, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Non Alcoholic Steatohepatitis Treatment Industry Forecast” looks at past sales and reviews total world Non Alcoholic Steatohepatitis Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Non Alcoholic Steatohepatitis Treatment sales for 2023 through 2029. With Non Alcoholic Steatohepatitis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non Alcoholic Steatohepatitis Treatment industry.
This Insight Report provides a comprehensive analysis of the global Non Alcoholic Steatohepatitis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non Alcoholic Steatohepatitis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Non Alcoholic Steatohepatitis Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non Alcoholic Steatohepatitis Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non Alcoholic Steatohepatitis Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Non Alcoholic Steatohepatitis Treatment market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Non Alcoholic Steatohepatitis Treatment market?
What factors are driving Non Alcoholic Steatohepatitis Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Non Alcoholic Steatohepatitis Treatment market opportunities vary by end market size?
How does Non Alcoholic Steatohepatitis Treatment break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
The global Non Alcoholic Steatohepatitis Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Non Alcoholic Steatohepatitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Non Alcoholic Steatohepatitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Non Alcoholic Steatohepatitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Non Alcoholic Steatohepatitis Treatment players cover AstraZeneca Plc., Tobira Therapeutics Inc., Galmed Pharmaceuticals, Genfit SA, Zydus Cadila, Bristol Myers Squibb, Gilead Science, Conatus Pharmaceuticals Inc. and Novo Nordisk A/S, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Non Alcoholic Steatohepatitis Treatment Industry Forecast” looks at past sales and reviews total world Non Alcoholic Steatohepatitis Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Non Alcoholic Steatohepatitis Treatment sales for 2023 through 2029. With Non Alcoholic Steatohepatitis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non Alcoholic Steatohepatitis Treatment industry.
This Insight Report provides a comprehensive analysis of the global Non Alcoholic Steatohepatitis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non Alcoholic Steatohepatitis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Non Alcoholic Steatohepatitis Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non Alcoholic Steatohepatitis Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non Alcoholic Steatohepatitis Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Non Alcoholic Steatohepatitis Treatment market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Vitamin E And Pioglitazone
- Ocaliva
- Elafibranor
- Obeticholic Acid
- Hospital Pharmacies
- Retail And Specialty Pharmacies
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AstraZeneca Plc.
- Tobira Therapeutics Inc.
- Galmed Pharmaceuticals
- Genfit SA
- Zydus Cadila
- Bristol Myers Squibb
- Gilead Science
- Conatus Pharmaceuticals Inc.
- Novo Nordisk A/S
- Immuron Ltd.
- Raptor Pharmaceutical Corporation
- Inventiva Pharma
- NGM Biopharmaceuticals Inc.
- Galectin Therapeutics Inc.
- Madrigal Pharmaceuticals
- Gemphire Therapeutics
What is the 10-year outlook for the global Non Alcoholic Steatohepatitis Treatment market?
What factors are driving Non Alcoholic Steatohepatitis Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Non Alcoholic Steatohepatitis Treatment market opportunities vary by end market size?
How does Non Alcoholic Steatohepatitis Treatment break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non Alcoholic Steatohepatitis Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Non Alcoholic Steatohepatitis Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Non Alcoholic Steatohepatitis Treatment by Country/Region, 2018, 2022 & 2029
2.2 Non Alcoholic Steatohepatitis Treatment Segment by Type
2.2.1 Vitamin E And Pioglitazone
2.2.2 Ocaliva
2.2.3 Elafibranor
2.2.4 Obeticholic Acid
2.3 Non Alcoholic Steatohepatitis Treatment Sales by Type
2.3.1 Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Non Alcoholic Steatohepatitis Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Non Alcoholic Steatohepatitis Treatment Sale Price by Type (2018-2023)
2.4 Non Alcoholic Steatohepatitis Treatment Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail And Specialty Pharmacies
2.5 Non Alcoholic Steatohepatitis Treatment Sales by Application
2.5.1 Global Non Alcoholic Steatohepatitis Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Non Alcoholic Steatohepatitis Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Non Alcoholic Steatohepatitis Treatment Sale Price by Application (2018-2023)
3 GLOBAL NON ALCOHOLIC STEATOHEPATITIS TREATMENT BY COMPANY
3.1 Global Non Alcoholic Steatohepatitis Treatment Breakdown Data by Company
3.1.1 Global Non Alcoholic Steatohepatitis Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Company (2018-2023)
3.2 Global Non Alcoholic Steatohepatitis Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Non Alcoholic Steatohepatitis Treatment Revenue by Company (2018-2023)
3.2.2 Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Non Alcoholic Steatohepatitis Treatment Sale Price by Company
3.4 Key Manufacturers Non Alcoholic Steatohepatitis Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non Alcoholic Steatohepatitis Treatment Product Location Distribution
3.4.2 Players Non Alcoholic Steatohepatitis Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NON ALCOHOLIC STEATOHEPATITIS TREATMENT BY GEOGRAPHIC REGION
4.1 World Historic Non Alcoholic Steatohepatitis Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Non Alcoholic Steatohepatitis Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Non Alcoholic Steatohepatitis Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Non Alcoholic Steatohepatitis Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Non Alcoholic Steatohepatitis Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Non Alcoholic Steatohepatitis Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Non Alcoholic Steatohepatitis Treatment Sales Growth
4.4 APAC Non Alcoholic Steatohepatitis Treatment Sales Growth
4.5 Europe Non Alcoholic Steatohepatitis Treatment Sales Growth
4.6 Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales Growth
5 AMERICAS
5.1 Americas Non Alcoholic Steatohepatitis Treatment Sales by Country
5.1.1 Americas Non Alcoholic Steatohepatitis Treatment Sales by Country (2018-2023)
5.1.2 Americas Non Alcoholic Steatohepatitis Treatment Revenue by Country (2018-2023)
5.2 Americas Non Alcoholic Steatohepatitis Treatment Sales by Type
5.3 Americas Non Alcoholic Steatohepatitis Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non Alcoholic Steatohepatitis Treatment Sales by Region
6.1.1 APAC Non Alcoholic Steatohepatitis Treatment Sales by Region (2018-2023)
6.1.2 APAC Non Alcoholic Steatohepatitis Treatment Revenue by Region (2018-2023)
6.2 APAC Non Alcoholic Steatohepatitis Treatment Sales by Type
6.3 APAC Non Alcoholic Steatohepatitis Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non Alcoholic Steatohepatitis Treatment by Country
7.1.1 Europe Non Alcoholic Steatohepatitis Treatment Sales by Country (2018-2023)
7.1.2 Europe Non Alcoholic Steatohepatitis Treatment Revenue by Country (2018-2023)
7.2 Europe Non Alcoholic Steatohepatitis Treatment Sales by Type
7.3 Europe Non Alcoholic Steatohepatitis Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non Alcoholic Steatohepatitis Treatment by Country
8.1.1 Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Non Alcoholic Steatohepatitis Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales by Type
8.3 Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non Alcoholic Steatohepatitis Treatment
10.3 Manufacturing Process Analysis of Non Alcoholic Steatohepatitis Treatment
10.4 Industry Chain Structure of Non Alcoholic Steatohepatitis Treatment
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non Alcoholic Steatohepatitis Treatment Distributors
11.3 Non Alcoholic Steatohepatitis Treatment Customer
12 WORLD FORECAST REVIEW FOR NON ALCOHOLIC STEATOHEPATITIS TREATMENT BY GEOGRAPHIC REGION
12.1 Global Non Alcoholic Steatohepatitis Treatment Market Size Forecast by Region
12.1.1 Global Non Alcoholic Steatohepatitis Treatment Forecast by Region (2024-2029)
12.1.2 Global Non Alcoholic Steatohepatitis Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Non Alcoholic Steatohepatitis Treatment Forecast by Type
12.7 Global Non Alcoholic Steatohepatitis Treatment Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca Plc.
13.1.1 AstraZeneca Plc. Company Information
13.1.2 AstraZeneca Plc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.1.3 AstraZeneca Plc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 AstraZeneca Plc. Main Business Overview
13.1.5 AstraZeneca Plc. Latest Developments
13.2 Tobira Therapeutics Inc.
13.2.1 Tobira Therapeutics Inc. Company Information
13.2.2 Tobira Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.2.3 Tobira Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Tobira Therapeutics Inc. Main Business Overview
13.2.5 Tobira Therapeutics Inc. Latest Developments
13.3 Galmed Pharmaceuticals
13.3.1 Galmed Pharmaceuticals Company Information
13.3.2 Galmed Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.3.3 Galmed Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Galmed Pharmaceuticals Main Business Overview
13.3.5 Galmed Pharmaceuticals Latest Developments
13.4 Genfit SA
13.4.1 Genfit SA Company Information
13.4.2 Genfit SA Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.4.3 Genfit SA Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Genfit SA Main Business Overview
13.4.5 Genfit SA Latest Developments
13.5 Zydus Cadila
13.5.1 Zydus Cadila Company Information
13.5.2 Zydus Cadila Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.5.3 Zydus Cadila Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Zydus Cadila Main Business Overview
13.5.5 Zydus Cadila Latest Developments
13.6 Bristol Myers Squibb
13.6.1 Bristol Myers Squibb Company Information
13.6.2 Bristol Myers Squibb Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.6.3 Bristol Myers Squibb Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bristol Myers Squibb Main Business Overview
13.6.5 Bristol Myers Squibb Latest Developments
13.7 Gilead Science
13.7.1 Gilead Science Company Information
13.7.2 Gilead Science Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.7.3 Gilead Science Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Gilead Science Main Business Overview
13.7.5 Gilead Science Latest Developments
13.8 Conatus Pharmaceuticals Inc.
13.8.1 Conatus Pharmaceuticals Inc. Company Information
13.8.2 Conatus Pharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.8.3 Conatus Pharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Conatus Pharmaceuticals Inc. Main Business Overview
13.8.5 Conatus Pharmaceuticals Inc. Latest Developments
13.9 Novo Nordisk A/S
13.9.1 Novo Nordisk A/S Company Information
13.9.2 Novo Nordisk A/S Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.9.3 Novo Nordisk A/S Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Novo Nordisk A/S Main Business Overview
13.9.5 Novo Nordisk A/S Latest Developments
13.10 Immuron Ltd.
13.10.1 Immuron Ltd. Company Information
13.10.2 Immuron Ltd. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.10.3 Immuron Ltd. Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Immuron Ltd. Main Business Overview
13.10.5 Immuron Ltd. Latest Developments
13.11 Raptor Pharmaceutical Corporation
13.11.1 Raptor Pharmaceutical Corporation Company Information
13.11.2 Raptor Pharmaceutical Corporation Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.11.3 Raptor Pharmaceutical Corporation Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Raptor Pharmaceutical Corporation Main Business Overview
13.11.5 Raptor Pharmaceutical Corporation Latest Developments
13.12 Inventiva Pharma
13.12.1 Inventiva Pharma Company Information
13.12.2 Inventiva Pharma Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.12.3 Inventiva Pharma Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Inventiva Pharma Main Business Overview
13.12.5 Inventiva Pharma Latest Developments
13.13 NGM Biopharmaceuticals Inc.
13.13.1 NGM Biopharmaceuticals Inc. Company Information
13.13.2 NGM Biopharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.13.3 NGM Biopharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 NGM Biopharmaceuticals Inc. Main Business Overview
13.13.5 NGM Biopharmaceuticals Inc. Latest Developments
13.14 Galectin Therapeutics Inc.
13.14.1 Galectin Therapeutics Inc. Company Information
13.14.2 Galectin Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.14.3 Galectin Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Galectin Therapeutics Inc. Main Business Overview
13.14.5 Galectin Therapeutics Inc. Latest Developments
13.15 Madrigal Pharmaceuticals
13.15.1 Madrigal Pharmaceuticals Company Information
13.15.2 Madrigal Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.15.3 Madrigal Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Madrigal Pharmaceuticals Main Business Overview
13.15.5 Madrigal Pharmaceuticals Latest Developments
13.16 Gemphire Therapeutics
13.16.1 Gemphire Therapeutics Company Information
13.16.2 Gemphire Therapeutics Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.16.3 Gemphire Therapeutics Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Gemphire Therapeutics Main Business Overview
13.16.5 Gemphire Therapeutics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non Alcoholic Steatohepatitis Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Non Alcoholic Steatohepatitis Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Non Alcoholic Steatohepatitis Treatment by Country/Region, 2018, 2022 & 2029
2.2 Non Alcoholic Steatohepatitis Treatment Segment by Type
2.2.1 Vitamin E And Pioglitazone
2.2.2 Ocaliva
2.2.3 Elafibranor
2.2.4 Obeticholic Acid
2.3 Non Alcoholic Steatohepatitis Treatment Sales by Type
2.3.1 Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Non Alcoholic Steatohepatitis Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Non Alcoholic Steatohepatitis Treatment Sale Price by Type (2018-2023)
2.4 Non Alcoholic Steatohepatitis Treatment Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail And Specialty Pharmacies
2.5 Non Alcoholic Steatohepatitis Treatment Sales by Application
2.5.1 Global Non Alcoholic Steatohepatitis Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Non Alcoholic Steatohepatitis Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Non Alcoholic Steatohepatitis Treatment Sale Price by Application (2018-2023)
3 GLOBAL NON ALCOHOLIC STEATOHEPATITIS TREATMENT BY COMPANY
3.1 Global Non Alcoholic Steatohepatitis Treatment Breakdown Data by Company
3.1.1 Global Non Alcoholic Steatohepatitis Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Company (2018-2023)
3.2 Global Non Alcoholic Steatohepatitis Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Non Alcoholic Steatohepatitis Treatment Revenue by Company (2018-2023)
3.2.2 Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Non Alcoholic Steatohepatitis Treatment Sale Price by Company
3.4 Key Manufacturers Non Alcoholic Steatohepatitis Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non Alcoholic Steatohepatitis Treatment Product Location Distribution
3.4.2 Players Non Alcoholic Steatohepatitis Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NON ALCOHOLIC STEATOHEPATITIS TREATMENT BY GEOGRAPHIC REGION
4.1 World Historic Non Alcoholic Steatohepatitis Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Non Alcoholic Steatohepatitis Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Non Alcoholic Steatohepatitis Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Non Alcoholic Steatohepatitis Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Non Alcoholic Steatohepatitis Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Non Alcoholic Steatohepatitis Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Non Alcoholic Steatohepatitis Treatment Sales Growth
4.4 APAC Non Alcoholic Steatohepatitis Treatment Sales Growth
4.5 Europe Non Alcoholic Steatohepatitis Treatment Sales Growth
4.6 Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales Growth
5 AMERICAS
5.1 Americas Non Alcoholic Steatohepatitis Treatment Sales by Country
5.1.1 Americas Non Alcoholic Steatohepatitis Treatment Sales by Country (2018-2023)
5.1.2 Americas Non Alcoholic Steatohepatitis Treatment Revenue by Country (2018-2023)
5.2 Americas Non Alcoholic Steatohepatitis Treatment Sales by Type
5.3 Americas Non Alcoholic Steatohepatitis Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non Alcoholic Steatohepatitis Treatment Sales by Region
6.1.1 APAC Non Alcoholic Steatohepatitis Treatment Sales by Region (2018-2023)
6.1.2 APAC Non Alcoholic Steatohepatitis Treatment Revenue by Region (2018-2023)
6.2 APAC Non Alcoholic Steatohepatitis Treatment Sales by Type
6.3 APAC Non Alcoholic Steatohepatitis Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Non Alcoholic Steatohepatitis Treatment by Country
7.1.1 Europe Non Alcoholic Steatohepatitis Treatment Sales by Country (2018-2023)
7.1.2 Europe Non Alcoholic Steatohepatitis Treatment Revenue by Country (2018-2023)
7.2 Europe Non Alcoholic Steatohepatitis Treatment Sales by Type
7.3 Europe Non Alcoholic Steatohepatitis Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non Alcoholic Steatohepatitis Treatment by Country
8.1.1 Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Non Alcoholic Steatohepatitis Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales by Type
8.3 Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non Alcoholic Steatohepatitis Treatment
10.3 Manufacturing Process Analysis of Non Alcoholic Steatohepatitis Treatment
10.4 Industry Chain Structure of Non Alcoholic Steatohepatitis Treatment
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non Alcoholic Steatohepatitis Treatment Distributors
11.3 Non Alcoholic Steatohepatitis Treatment Customer
12 WORLD FORECAST REVIEW FOR NON ALCOHOLIC STEATOHEPATITIS TREATMENT BY GEOGRAPHIC REGION
12.1 Global Non Alcoholic Steatohepatitis Treatment Market Size Forecast by Region
12.1.1 Global Non Alcoholic Steatohepatitis Treatment Forecast by Region (2024-2029)
12.1.2 Global Non Alcoholic Steatohepatitis Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Non Alcoholic Steatohepatitis Treatment Forecast by Type
12.7 Global Non Alcoholic Steatohepatitis Treatment Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca Plc.
13.1.1 AstraZeneca Plc. Company Information
13.1.2 AstraZeneca Plc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.1.3 AstraZeneca Plc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 AstraZeneca Plc. Main Business Overview
13.1.5 AstraZeneca Plc. Latest Developments
13.2 Tobira Therapeutics Inc.
13.2.1 Tobira Therapeutics Inc. Company Information
13.2.2 Tobira Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.2.3 Tobira Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Tobira Therapeutics Inc. Main Business Overview
13.2.5 Tobira Therapeutics Inc. Latest Developments
13.3 Galmed Pharmaceuticals
13.3.1 Galmed Pharmaceuticals Company Information
13.3.2 Galmed Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.3.3 Galmed Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Galmed Pharmaceuticals Main Business Overview
13.3.5 Galmed Pharmaceuticals Latest Developments
13.4 Genfit SA
13.4.1 Genfit SA Company Information
13.4.2 Genfit SA Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.4.3 Genfit SA Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Genfit SA Main Business Overview
13.4.5 Genfit SA Latest Developments
13.5 Zydus Cadila
13.5.1 Zydus Cadila Company Information
13.5.2 Zydus Cadila Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.5.3 Zydus Cadila Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Zydus Cadila Main Business Overview
13.5.5 Zydus Cadila Latest Developments
13.6 Bristol Myers Squibb
13.6.1 Bristol Myers Squibb Company Information
13.6.2 Bristol Myers Squibb Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.6.3 Bristol Myers Squibb Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bristol Myers Squibb Main Business Overview
13.6.5 Bristol Myers Squibb Latest Developments
13.7 Gilead Science
13.7.1 Gilead Science Company Information
13.7.2 Gilead Science Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.7.3 Gilead Science Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Gilead Science Main Business Overview
13.7.5 Gilead Science Latest Developments
13.8 Conatus Pharmaceuticals Inc.
13.8.1 Conatus Pharmaceuticals Inc. Company Information
13.8.2 Conatus Pharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.8.3 Conatus Pharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Conatus Pharmaceuticals Inc. Main Business Overview
13.8.5 Conatus Pharmaceuticals Inc. Latest Developments
13.9 Novo Nordisk A/S
13.9.1 Novo Nordisk A/S Company Information
13.9.2 Novo Nordisk A/S Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.9.3 Novo Nordisk A/S Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Novo Nordisk A/S Main Business Overview
13.9.5 Novo Nordisk A/S Latest Developments
13.10 Immuron Ltd.
13.10.1 Immuron Ltd. Company Information
13.10.2 Immuron Ltd. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.10.3 Immuron Ltd. Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Immuron Ltd. Main Business Overview
13.10.5 Immuron Ltd. Latest Developments
13.11 Raptor Pharmaceutical Corporation
13.11.1 Raptor Pharmaceutical Corporation Company Information
13.11.2 Raptor Pharmaceutical Corporation Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.11.3 Raptor Pharmaceutical Corporation Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Raptor Pharmaceutical Corporation Main Business Overview
13.11.5 Raptor Pharmaceutical Corporation Latest Developments
13.12 Inventiva Pharma
13.12.1 Inventiva Pharma Company Information
13.12.2 Inventiva Pharma Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.12.3 Inventiva Pharma Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Inventiva Pharma Main Business Overview
13.12.5 Inventiva Pharma Latest Developments
13.13 NGM Biopharmaceuticals Inc.
13.13.1 NGM Biopharmaceuticals Inc. Company Information
13.13.2 NGM Biopharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.13.3 NGM Biopharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 NGM Biopharmaceuticals Inc. Main Business Overview
13.13.5 NGM Biopharmaceuticals Inc. Latest Developments
13.14 Galectin Therapeutics Inc.
13.14.1 Galectin Therapeutics Inc. Company Information
13.14.2 Galectin Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.14.3 Galectin Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Galectin Therapeutics Inc. Main Business Overview
13.14.5 Galectin Therapeutics Inc. Latest Developments
13.15 Madrigal Pharmaceuticals
13.15.1 Madrigal Pharmaceuticals Company Information
13.15.2 Madrigal Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.15.3 Madrigal Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Madrigal Pharmaceuticals Main Business Overview
13.15.5 Madrigal Pharmaceuticals Latest Developments
13.16 Gemphire Therapeutics
13.16.1 Gemphire Therapeutics Company Information
13.16.2 Gemphire Therapeutics Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
13.16.3 Gemphire Therapeutics Non Alcoholic Steatohepatitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Gemphire Therapeutics Main Business Overview
13.16.5 Gemphire Therapeutics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Non Alcoholic Steatohepatitis Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Non Alcoholic Steatohepatitis Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Vitamin E And Pioglitazone
Table 4. Major Players of Ocaliva
Table 5. Major Players of Elafibranor
Table 6. Major Players of Obeticholic Acid
Table 7. Global Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2023) & (K Units)
Table 8. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
Table 9. Global Non Alcoholic Steatohepatitis Treatment Revenue by Type (2018-2023) & ($ million)
Table 10. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Type (2018-2023)
Table 11. Global Non Alcoholic Steatohepatitis Treatment Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2023) & (K Units)
Table 13. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Application (2018-2023)
Table 14. Global Non Alcoholic Steatohepatitis Treatment Revenue by Application (2018-2023)
Table 15. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Application (2018-2023)
Table 16. Global Non Alcoholic Steatohepatitis Treatment Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Non Alcoholic Steatohepatitis Treatment Sales by Company (2018-2023) & (K Units)
Table 18. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Company (2018-2023)
Table 19. Global Non Alcoholic Steatohepatitis Treatment Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Company (2018-2023)
Table 21. Global Non Alcoholic Steatohepatitis Treatment Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Non Alcoholic Steatohepatitis Treatment Producing Area Distribution and Sales Area
Table 23. Players Non Alcoholic Steatohepatitis Treatment Products Offered
Table 24. Non Alcoholic Steatohepatitis Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Non Alcoholic Steatohepatitis Treatment Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share Geographic Region (2018-2023)
Table 29. Global Non Alcoholic Steatohepatitis Treatment Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Non Alcoholic Steatohepatitis Treatment Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country/Region (2018-2023)
Table 33. Global Non Alcoholic Steatohepatitis Treatment Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Non Alcoholic Steatohepatitis Treatment Sales by Country (2018-2023) & (K Units)
Table 36. Americas Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country (2018-2023)
Table 37. Americas Non Alcoholic Steatohepatitis Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country (2018-2023)
Table 39. Americas Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2023) & (K Units)
Table 40. Americas Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2023) & (K Units)
Table 41. APAC Non Alcoholic Steatohepatitis Treatment Sales by Region (2018-2023) & (K Units)
Table 42. APAC Non Alcoholic Steatohepatitis Treatment Sales Market Share by Region (2018-2023)
Table 43. APAC Non Alcoholic Steatohepatitis Treatment Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Region (2018-2023)
Table 45. APAC Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2023) & (K Units)
Table 46. APAC Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2023) & (K Units)
Table 47. Europe Non Alcoholic Steatohepatitis Treatment Sales by Country (2018-2023) & (K Units)
Table 48. Europe Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country (2018-2023)
Table 49. Europe Non Alcoholic Steatohepatitis Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country (2018-2023)
Table 51. Europe Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2023) & (K Units)
Table 52. Europe Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Non Alcoholic Steatohepatitis Treatment
Table 60. Key Market Challenges & Risks of Non Alcoholic Steatohepatitis Treatment
Table 61. Key Industry Trends of Non Alcoholic Steatohepatitis Treatment
Table 62. Non Alcoholic Steatohepatitis Treatment Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Non Alcoholic Steatohepatitis Treatment Distributors List
Table 65. Non Alcoholic Steatohepatitis Treatment Customer List
Table 66. Global Non Alcoholic Steatohepatitis Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Non Alcoholic Steatohepatitis Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Non Alcoholic Steatohepatitis Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Non Alcoholic Steatohepatitis Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Non Alcoholic Steatohepatitis Treatment Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Non Alcoholic Steatohepatitis Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. AstraZeneca Plc. Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 81. AstraZeneca Plc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 82. AstraZeneca Plc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. AstraZeneca Plc. Main Business
Table 84. AstraZeneca Plc. Latest Developments
Table 85. Tobira Therapeutics Inc. Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 86. Tobira Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 87. Tobira Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Tobira Therapeutics Inc. Main Business
Table 89. Tobira Therapeutics Inc. Latest Developments
Table 90. Galmed Pharmaceuticals Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 91. Galmed Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 92. Galmed Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Galmed Pharmaceuticals Main Business
Table 94. Galmed Pharmaceuticals Latest Developments
Table 95. Genfit SA Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 96. Genfit SA Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 97. Genfit SA Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Genfit SA Main Business
Table 99. Genfit SA Latest Developments
Table 100. Zydus Cadila Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 101. Zydus Cadila Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 102. Zydus Cadila Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Zydus Cadila Main Business
Table 104. Zydus Cadila Latest Developments
Table 105. Bristol Myers Squibb Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 106. Bristol Myers Squibb Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 107. Bristol Myers Squibb Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Bristol Myers Squibb Main Business
Table 109. Bristol Myers Squibb Latest Developments
Table 110. Gilead Science Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 111. Gilead Science Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 112. Gilead Science Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Gilead Science Main Business
Table 114. Gilead Science Latest Developments
Table 115. Conatus Pharmaceuticals Inc. Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 116. Conatus Pharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 117. Conatus Pharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Conatus Pharmaceuticals Inc. Main Business
Table 119. Conatus Pharmaceuticals Inc. Latest Developments
Table 120. Novo Nordisk A/S Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 121. Novo Nordisk A/S Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 122. Novo Nordisk A/S Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Novo Nordisk A/S Main Business
Table 124. Novo Nordisk A/S Latest Developments
Table 125. Immuron Ltd. Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 126. Immuron Ltd. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 127. Immuron Ltd. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Immuron Ltd. Main Business
Table 129. Immuron Ltd. Latest Developments
Table 130. Raptor Pharmaceutical Corporation Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 131. Raptor Pharmaceutical Corporation Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 132. Raptor Pharmaceutical Corporation Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Raptor Pharmaceutical Corporation Main Business
Table 134. Raptor Pharmaceutical Corporation Latest Developments
Table 135. Inventiva Pharma Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 136. Inventiva Pharma Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 137. Inventiva Pharma Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Inventiva Pharma Main Business
Table 139. Inventiva Pharma Latest Developments
Table 140. NGM Biopharmaceuticals Inc. Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 141. NGM Biopharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 142. NGM Biopharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. NGM Biopharmaceuticals Inc. Main Business
Table 144. NGM Biopharmaceuticals Inc. Latest Developments
Table 145. Galectin Therapeutics Inc. Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 146. Galectin Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 147. Galectin Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. Galectin Therapeutics Inc. Main Business
Table 149. Galectin Therapeutics Inc. Latest Developments
Table 150. Madrigal Pharmaceuticals Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 151. Madrigal Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 152. Madrigal Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. Madrigal Pharmaceuticals Main Business
Table 154. Madrigal Pharmaceuticals Latest Developments
Table 155. Gemphire Therapeutics Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 156. Gemphire Therapeutics Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 157. Gemphire Therapeutics Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 158. Gemphire Therapeutics Main Business
Table 159. Gemphire Therapeutics Latest Developments
Table 1. Non Alcoholic Steatohepatitis Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Non Alcoholic Steatohepatitis Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Vitamin E And Pioglitazone
Table 4. Major Players of Ocaliva
Table 5. Major Players of Elafibranor
Table 6. Major Players of Obeticholic Acid
Table 7. Global Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2023) & (K Units)
Table 8. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
Table 9. Global Non Alcoholic Steatohepatitis Treatment Revenue by Type (2018-2023) & ($ million)
Table 10. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Type (2018-2023)
Table 11. Global Non Alcoholic Steatohepatitis Treatment Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2023) & (K Units)
Table 13. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Application (2018-2023)
Table 14. Global Non Alcoholic Steatohepatitis Treatment Revenue by Application (2018-2023)
Table 15. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Application (2018-2023)
Table 16. Global Non Alcoholic Steatohepatitis Treatment Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Non Alcoholic Steatohepatitis Treatment Sales by Company (2018-2023) & (K Units)
Table 18. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Company (2018-2023)
Table 19. Global Non Alcoholic Steatohepatitis Treatment Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Company (2018-2023)
Table 21. Global Non Alcoholic Steatohepatitis Treatment Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Non Alcoholic Steatohepatitis Treatment Producing Area Distribution and Sales Area
Table 23. Players Non Alcoholic Steatohepatitis Treatment Products Offered
Table 24. Non Alcoholic Steatohepatitis Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Non Alcoholic Steatohepatitis Treatment Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share Geographic Region (2018-2023)
Table 29. Global Non Alcoholic Steatohepatitis Treatment Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Non Alcoholic Steatohepatitis Treatment Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country/Region (2018-2023)
Table 33. Global Non Alcoholic Steatohepatitis Treatment Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Non Alcoholic Steatohepatitis Treatment Sales by Country (2018-2023) & (K Units)
Table 36. Americas Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country (2018-2023)
Table 37. Americas Non Alcoholic Steatohepatitis Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country (2018-2023)
Table 39. Americas Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2023) & (K Units)
Table 40. Americas Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2023) & (K Units)
Table 41. APAC Non Alcoholic Steatohepatitis Treatment Sales by Region (2018-2023) & (K Units)
Table 42. APAC Non Alcoholic Steatohepatitis Treatment Sales Market Share by Region (2018-2023)
Table 43. APAC Non Alcoholic Steatohepatitis Treatment Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Region (2018-2023)
Table 45. APAC Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2023) & (K Units)
Table 46. APAC Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2023) & (K Units)
Table 47. Europe Non Alcoholic Steatohepatitis Treatment Sales by Country (2018-2023) & (K Units)
Table 48. Europe Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country (2018-2023)
Table 49. Europe Non Alcoholic Steatohepatitis Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country (2018-2023)
Table 51. Europe Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2023) & (K Units)
Table 52. Europe Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Non Alcoholic Steatohepatitis Treatment
Table 60. Key Market Challenges & Risks of Non Alcoholic Steatohepatitis Treatment
Table 61. Key Industry Trends of Non Alcoholic Steatohepatitis Treatment
Table 62. Non Alcoholic Steatohepatitis Treatment Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Non Alcoholic Steatohepatitis Treatment Distributors List
Table 65. Non Alcoholic Steatohepatitis Treatment Customer List
Table 66. Global Non Alcoholic Steatohepatitis Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Non Alcoholic Steatohepatitis Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Non Alcoholic Steatohepatitis Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Non Alcoholic Steatohepatitis Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Non Alcoholic Steatohepatitis Treatment Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Non Alcoholic Steatohepatitis Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Non Alcoholic Steatohepatitis Treatment Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. AstraZeneca Plc. Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 81. AstraZeneca Plc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 82. AstraZeneca Plc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. AstraZeneca Plc. Main Business
Table 84. AstraZeneca Plc. Latest Developments
Table 85. Tobira Therapeutics Inc. Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 86. Tobira Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 87. Tobira Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Tobira Therapeutics Inc. Main Business
Table 89. Tobira Therapeutics Inc. Latest Developments
Table 90. Galmed Pharmaceuticals Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 91. Galmed Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 92. Galmed Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Galmed Pharmaceuticals Main Business
Table 94. Galmed Pharmaceuticals Latest Developments
Table 95. Genfit SA Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 96. Genfit SA Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 97. Genfit SA Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Genfit SA Main Business
Table 99. Genfit SA Latest Developments
Table 100. Zydus Cadila Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 101. Zydus Cadila Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 102. Zydus Cadila Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Zydus Cadila Main Business
Table 104. Zydus Cadila Latest Developments
Table 105. Bristol Myers Squibb Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 106. Bristol Myers Squibb Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 107. Bristol Myers Squibb Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Bristol Myers Squibb Main Business
Table 109. Bristol Myers Squibb Latest Developments
Table 110. Gilead Science Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 111. Gilead Science Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 112. Gilead Science Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Gilead Science Main Business
Table 114. Gilead Science Latest Developments
Table 115. Conatus Pharmaceuticals Inc. Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 116. Conatus Pharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 117. Conatus Pharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Conatus Pharmaceuticals Inc. Main Business
Table 119. Conatus Pharmaceuticals Inc. Latest Developments
Table 120. Novo Nordisk A/S Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 121. Novo Nordisk A/S Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 122. Novo Nordisk A/S Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Novo Nordisk A/S Main Business
Table 124. Novo Nordisk A/S Latest Developments
Table 125. Immuron Ltd. Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 126. Immuron Ltd. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 127. Immuron Ltd. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Immuron Ltd. Main Business
Table 129. Immuron Ltd. Latest Developments
Table 130. Raptor Pharmaceutical Corporation Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 131. Raptor Pharmaceutical Corporation Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 132. Raptor Pharmaceutical Corporation Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Raptor Pharmaceutical Corporation Main Business
Table 134. Raptor Pharmaceutical Corporation Latest Developments
Table 135. Inventiva Pharma Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 136. Inventiva Pharma Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 137. Inventiva Pharma Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Inventiva Pharma Main Business
Table 139. Inventiva Pharma Latest Developments
Table 140. NGM Biopharmaceuticals Inc. Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 141. NGM Biopharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 142. NGM Biopharmaceuticals Inc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. NGM Biopharmaceuticals Inc. Main Business
Table 144. NGM Biopharmaceuticals Inc. Latest Developments
Table 145. Galectin Therapeutics Inc. Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 146. Galectin Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 147. Galectin Therapeutics Inc. Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. Galectin Therapeutics Inc. Main Business
Table 149. Galectin Therapeutics Inc. Latest Developments
Table 150. Madrigal Pharmaceuticals Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 151. Madrigal Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 152. Madrigal Pharmaceuticals Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. Madrigal Pharmaceuticals Main Business
Table 154. Madrigal Pharmaceuticals Latest Developments
Table 155. Gemphire Therapeutics Basic Information, Non Alcoholic Steatohepatitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 156. Gemphire Therapeutics Non Alcoholic Steatohepatitis Treatment Product Portfolios and Specifications
Table 157. Gemphire Therapeutics Non Alcoholic Steatohepatitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 158. Gemphire Therapeutics Main Business
Table 159. Gemphire Therapeutics Latest Developments
LIST OF FIGURES
Figure 1. Picture of Non Alcoholic Steatohepatitis Treatment
Figure 2. Non Alcoholic Steatohepatitis Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non Alcoholic Steatohepatitis Treatment Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Non Alcoholic Steatohepatitis Treatment Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Non Alcoholic Steatohepatitis Treatment Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Vitamin E And Pioglitazone
Figure 10. Product Picture of Ocaliva
Figure 11. Product Picture of Elafibranor
Figure 12. Product Picture of Obeticholic Acid
Figure 13. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type in 2022
Figure 14. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Type (2018-2023)
Figure 15. Non Alcoholic Steatohepatitis Treatment Consumed in Hospital Pharmacies
Figure 16. Global Non Alcoholic Steatohepatitis Treatment Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 17. Non Alcoholic Steatohepatitis Treatment Consumed in Retail And Specialty Pharmacies
Figure 18. Global Non Alcoholic Steatohepatitis Treatment Market: Retail And Specialty Pharmacies (2018-2023) & (K Units)
Figure 19. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Application (2022)
Figure 20. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Application in 2022
Figure 21. Non Alcoholic Steatohepatitis Treatment Sales Market by Company in 2022 (K Units)
Figure 22. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Company in 2022
Figure 23. Non Alcoholic Steatohepatitis Treatment Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Company in 2022
Figure 25. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Non Alcoholic Steatohepatitis Treatment Sales 2018-2023 (K Units)
Figure 28. Americas Non Alcoholic Steatohepatitis Treatment Revenue 2018-2023 ($ Millions)
Figure 29. APAC Non Alcoholic Steatohepatitis Treatment Sales 2018-2023 (K Units)
Figure 30. APAC Non Alcoholic Steatohepatitis Treatment Revenue 2018-2023 ($ Millions)
Figure 31. Europe Non Alcoholic Steatohepatitis Treatment Sales 2018-2023 (K Units)
Figure 32. Europe Non Alcoholic Steatohepatitis Treatment Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Revenue 2018-2023 ($ Millions)
Figure 35. Americas Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country in 2022
Figure 36. Americas Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country in 2022
Figure 37. Americas Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
Figure 38. Americas Non Alcoholic Steatohepatitis Treatment Sales Market Share by Application (2018-2023)
Figure 39. United States Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Non Alcoholic Steatohepatitis Treatment Sales Market Share by Region in 2022
Figure 44. APAC Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Regions in 2022
Figure 45. APAC Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
Figure 46. APAC Non Alcoholic Steatohepatitis Treatment Sales Market Share by Application (2018-2023)
Figure 47. China Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country in 2022
Figure 55. Europe Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country in 2022
Figure 56. Europe Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
Figure 57. Europe Non Alcoholic Steatohepatitis Treatment Sales Market Share by Application (2018-2023)
Figure 58. Germany Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales Market Share by Application (2018-2023)
Figure 67. Egypt Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Non Alcoholic Steatohepatitis Treatment in 2022
Figure 73. Manufacturing Process Analysis of Non Alcoholic Steatohepatitis Treatment
Figure 74. Industry Chain Structure of Non Alcoholic Steatohepatitis Treatment
Figure 75. Channels of Distribution
Figure 76. Global Non Alcoholic Steatohepatitis Treatment Sales Market Forecast by Region (2024-2029)
Figure 77. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Non Alcoholic Steatohepatitis Treatment
Figure 2. Non Alcoholic Steatohepatitis Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Non Alcoholic Steatohepatitis Treatment Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Non Alcoholic Steatohepatitis Treatment Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Non Alcoholic Steatohepatitis Treatment Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Vitamin E And Pioglitazone
Figure 10. Product Picture of Ocaliva
Figure 11. Product Picture of Elafibranor
Figure 12. Product Picture of Obeticholic Acid
Figure 13. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type in 2022
Figure 14. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Type (2018-2023)
Figure 15. Non Alcoholic Steatohepatitis Treatment Consumed in Hospital Pharmacies
Figure 16. Global Non Alcoholic Steatohepatitis Treatment Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 17. Non Alcoholic Steatohepatitis Treatment Consumed in Retail And Specialty Pharmacies
Figure 18. Global Non Alcoholic Steatohepatitis Treatment Market: Retail And Specialty Pharmacies (2018-2023) & (K Units)
Figure 19. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Application (2022)
Figure 20. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Application in 2022
Figure 21. Non Alcoholic Steatohepatitis Treatment Sales Market by Company in 2022 (K Units)
Figure 22. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Company in 2022
Figure 23. Non Alcoholic Steatohepatitis Treatment Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Company in 2022
Figure 25. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Non Alcoholic Steatohepatitis Treatment Sales 2018-2023 (K Units)
Figure 28. Americas Non Alcoholic Steatohepatitis Treatment Revenue 2018-2023 ($ Millions)
Figure 29. APAC Non Alcoholic Steatohepatitis Treatment Sales 2018-2023 (K Units)
Figure 30. APAC Non Alcoholic Steatohepatitis Treatment Revenue 2018-2023 ($ Millions)
Figure 31. Europe Non Alcoholic Steatohepatitis Treatment Sales 2018-2023 (K Units)
Figure 32. Europe Non Alcoholic Steatohepatitis Treatment Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Revenue 2018-2023 ($ Millions)
Figure 35. Americas Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country in 2022
Figure 36. Americas Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country in 2022
Figure 37. Americas Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
Figure 38. Americas Non Alcoholic Steatohepatitis Treatment Sales Market Share by Application (2018-2023)
Figure 39. United States Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Non Alcoholic Steatohepatitis Treatment Sales Market Share by Region in 2022
Figure 44. APAC Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Regions in 2022
Figure 45. APAC Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
Figure 46. APAC Non Alcoholic Steatohepatitis Treatment Sales Market Share by Application (2018-2023)
Figure 47. China Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country in 2022
Figure 55. Europe Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country in 2022
Figure 56. Europe Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
Figure 57. Europe Non Alcoholic Steatohepatitis Treatment Sales Market Share by Application (2018-2023)
Figure 58. Germany Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Non Alcoholic Steatohepatitis Treatment Sales Market Share by Application (2018-2023)
Figure 67. Egypt Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Non Alcoholic Steatohepatitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Non Alcoholic Steatohepatitis Treatment in 2022
Figure 73. Manufacturing Process Analysis of Non Alcoholic Steatohepatitis Treatment
Figure 74. Industry Chain Structure of Non Alcoholic Steatohepatitis Treatment
Figure 75. Channels of Distribution
Figure 76. Global Non Alcoholic Steatohepatitis Treatment Sales Market Forecast by Region (2024-2029)
Figure 77. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Non Alcoholic Steatohepatitis Treatment Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Non Alcoholic Steatohepatitis Treatment Revenue Market Share Forecast by Application (2024-2029)
